FAU own research funding: EFI / IZKF / EAM ...
Start date : 01.08.2025
End date : 31.01.2028
Possibly predicting high-risk, B cells are already impaired at first diagnosis of B-NHL. Focusing on CAR T cells, B cell regeneration after therapy is different from other diseases, contributing to infections and non-relapse mortality. Dissecting underlying mechanisms, B cell regeneration will be correlated with targeted and unspecific therapies using cell and serum analyses. Understanding the cross-talk of lymphoma dynamics and B cell function may delineate novel prophylactic interventions.